In today’s recent session, 0.57 million shares of the Adma Biologics Inc (NASDAQ:ADMA) have been traded, and its beta is 0.61. Most recently the company’s share price was $17.95, and it changed around -$0.45 or -2.43% from the last close, which brings the market valuation of the company to $4.18B. ADMA at last check was trading at a discount to its 52-week high of $18.42, offering almost -2.62% off that amount. The share price’s 52-week low was $3.06, which indicates that the recent value has risen by an impressive 82.95% since then. We note from Adma Biologics Inc’s average daily trading volume that its 10-day average is 3.78 million shares, with the 3-month average coming to 3.52 million.

Adma Biologics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended ADMA as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Adma Biologics Inc is expected to report earnings per share of 0.13 for the current quarter.

Adma Biologics Inc (NASDAQ:ADMA) trade information

Instantly ADMA has been showing red trend so far today with a performance of -2.43% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 18.48 on recent trading dayincreased the stock’s daily price by 2.87%. The company’s shares are currently up 297.18% year-to-date, but still down -1.47% over the last five days. On the other hand, Adma Biologics Inc (NASDAQ:ADMA) is 36.42% up in the 30-day period. We can see from the shorts that 8.75 million shares have been sold at a short interest cover period of 2.72 day(s).

The consensus price target as assigned by Wall Street analysts is $9.25, which translates to bulls needing to decrease their stock price by -94.05% from its current value. Analyst projections state that ADMA is forecast to be at a low of $4.5 and a high of $14.

Adma Biologics Inc (ADMA) estimates and forecasts

Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 1,200.00% in revenue this quarter, and will report an increase of 287.50% in the next quarter. The year-over-year growth rate is expected to be 57.10%, up from the previous year.

Consensus estimates provided by 3 financial analysts predict the company will bring in an average of 105.97M in revenue for the current quarter. 3 analysts expect Adma Biologics Inc to make 110.77M in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at 49.90%.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 38.68%.

ADMA Dividends

Adma Biologics Inc’s next quarterly earnings report is expected to be released on 2024-Nov-06.

Adma Biologics Inc (NASDAQ:ADMA)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 2.61% of Adma Biologics Inc shares, and 80.10% of them are in the hands of institutional investors. The stock currently has a share float of 82.25%. Adma Biologics Inc stock is held by 333.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 8.1462% of the shares, which is about 18.64 million shares worth $208.45 million.

VANGUARD GROUP INC, with 6.3426% or 14.52 million shares worth $162.3 million as of 2024-06-30, holds the second largest percentage of outstanding shares.

Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Mar 31, 2024. The former held 6.42 shares worth $114.95 million, making up 2.76% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 5.49 shares worth around $98.27 million, which represents about 2.36% of the total shares outstanding.